Scott & Selber Inc. increased its stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 8.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 15,196 shares of the biopharmaceutical company’s stock after acquiring an additional 1,163 shares during the period. Scott & Selber Inc.’s holdings in GW Pharmaceuticals PLC- were worth $2,620,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GWPH. Horan Capital Advisors LLC. acquired a new position in shares of GW Pharmaceuticals PLC- in the first quarter valued at approximately $25,000. Exane Derivatives acquired a new position in shares of GW Pharmaceuticals PLC- in the first quarter valued at approximately $28,000. TCG Advisors LP acquired a new position in shares of GW Pharmaceuticals PLC- in the first quarter valued at approximately $29,000. Institutional & Family Asset Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the first quarter valued at approximately $31,000. Finally, Paragon Capital Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the first quarter valued at approximately $34,000. Institutional investors and hedge funds own 78.92% of the company’s stock.

NASDAQ:GWPH traded up $0.46 during trading hours on Tuesday, reaching $159.84. 19,552 shares of the company were exchanged, compared to its average volume of 544,465. The firm has a market capitalization of $5.04 billion, a P/E ratio of -15.15 and a beta of 2.25. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 8.31 and a quick ratio of 7.59. The firm has a 50 day moving average of $167.03.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.96. The business had revenue of $72.04 million for the quarter, compared to the consensus estimate of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. The firm’s quarterly revenue was up 2096.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.25) earnings per share. On average, equities research analysts forecast that GW Pharmaceuticals PLC- will post -4.51 EPS for the current year.

In other GW Pharmaceuticals PLC- news, Director William A. Waldegrave sold 3,576 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $15.00, for a total transaction of $53,640.00. Following the completion of the sale, the director now directly owns 3,576 shares in the company, valued at $53,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christopher J. Tovey sold 64,800 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $14.61, for a total value of $946,728.00. Following the sale, the chief operating officer now owns 67,303 shares of the company’s stock, valued at $983,296.83. The disclosure for this sale can be found here. Insiders have sold 375,732 shares of company stock worth $5,676,404 in the last three months. 3.60% of the stock is currently owned by company insiders.

Several research firms have recently commented on GWPH. Piper Jaffray Companies upped their target price on GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. Morgan Stanley increased their price target on GW Pharmaceuticals PLC- to $238.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Guggenheim reissued a “buy” rating and set a $222.00 price target (up previously from $186.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 7th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $192.00 price target on the stock in a research report on Monday. Finally, Cowen reissued a “buy” rating and set a $200.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Friday, July 26th. Two research analysts have rated the stock with a sell rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $209.82.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: Why investors pay attention to retained earnings

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.